Novo Nordisk to stop selling its top brand Human Mixtard from India which is country's top selling insulin alone Rs. 800 Crore. Human Mixtard comes under DPCO and the company is reported to come up with new products in India.
Human Mixtard is a combination of two medicines, an intermediate-acting and a short-acting type of insulin.
Earlier in November 2024, Reuters reported that Novo Nordisk is gradually ending production of human insulin pens, as it spends billions to ramp up manufacturing of its popular obesity and diabetes injections.
Booming sales of the Danish drugmaker's new obesity and diabetes medicines, delivered in injection pens, have propelled it to become Europe's most valuable company by market value, at about USD 572 billion.
Médecins Sans Frontières (MSF) calls out Novo Nordisk for its double standard approach to diabetes, as the company plans to halt supply of human insulin pens.
MSF reported that The other insulin manufacturers now have an opportunity to address this double standard that has long existed toward people with diabetes in low- and middle-income countries. MSF demands that Sanofi and other insulin manufacturers come forward and take the responsibility of the market.
This move will allow Novo Nordisk to produce and sell more of their patented GLP-1 medicine for diabetes and obesity (marketed as Ozempic and Wegovy) in pen devices at high prices.
